| 22003 |
Cefiderocol |
Fetcroja® |
For the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options. Consideration should be given to official guidance on the appropriate use of antibacterial agents. |
Rapid Review complete |
5th June 2024 |
 |
| - |
Ceftaroline |
Zinforo® |
For the treatment of adult patients with complicated Skin and Soft Tissue Infections (cSSTI) or Community Acquired Pneumonia (CAP). |
Rapid Review complete |
12th October 2012 |
|
| - |
Ceftazidime/avibactam |
Zavicefta® |
For the treatment of CIAI, cUTI, HAP (including VAP) and gram negative infections due to aerobic Gram-negative organisms in adult patients with limited treatment options. |
Rapid Review complete |
13th June 2017 |
|
| 21003 |
Ceftazidime/avibactam |
Zavicefta® |
For paediatric patients aged three months and older for the treatment of: Complicated intra-abdominal infection (cIAI); Complicated urinary tract infection (cUTI), including pyelonephritis; Hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP); Infections due to aerobic Gram-negative organisms in patients with limited treatment options |
Rapid Review complete |
4th March 2021 |
|
| - |
Ceftolozane/tazobactam |
Zerbaxa® |
For the treatment of complicated urinary tract infections (cUTI), acute pyelonephritis and complicated intra-abdominal infections (cIAI) in adults. |
Rapid Review complete |
26th April 2016 |
|
| 21007 |
Cemiplimab |
Libtayo® |
Is indicated as monotherapy for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mCSCC or laCSCC) who are not candidates for curative surgery or curative radiation. |
NCPE Assessment Process Complete |
24th October 2023 |
|
| 21025 |
Cenobamate |
Ontozry® |
Adjunctive treatment of focal onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least two anti-epileptic medicinal products. |
NCPE Assessment Process Complete |
6th July 2023 |
|
| - |
Ceritinib |
Zykadia® |
For the treatment of adult patients with ALK-positive advanced NSCLC previously treated with crizotinib. |
Rapid Review complete |
22nd July 2015 |
|
| - |
Cerliponase alfa |
Brineura® |
For the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency. |
NCPE Assessment process complete |
26th March 2019 |
|
| - |
Certolizumab pegol |
Cimzia® |
For the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. |
Rapid Review complete |
14th November 2019 |
|
| - |
Certolizumab pegol |
Cimzia® |
For the treatment of moderate to severe rheumatoid arthritis. |
NCPE Assessment Process complete |
2nd September 2010 |
|
| 23049 |
Chlormethine gel |
Ledaga® |
Chlormethine gel (Ledaga®) is indicated for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-type CTCL) in adult patients. |
Rapid Review Complete |
11th November 2024 |
|
| 22033 |
Cholecalciferol |
Egostar® |
Prevention of vitamin D deficiency in adult patients with an identified risk, initial treatment of clinically relevant vitamin D deficiency, and as an adjunct to specific therapy for osteoporosis in patients with vitamin D deficiency or at risk of vitamin D insufficiency. |
Rapid Review complete |
23rd June 2022 |
|
| 21062 |
Cholic acid |
Orphacol® |
For the treatment of inborn errors in primary bile acid synthesis due to 3β-Hydroxy-Δ5-C27-steroid oxidoreductase deficiency or Δ4-3-Oxosteroid-5β-reductase deficiency in infants, children and adolescents aged one month to 18 years, and adults. |
Rapid Review complete |
12th January 2022 |
|
| - |
Ciclosporin |
Ikervis® |
For the treatment of severe keratitis in adult patients with dry eye disease (DED), which has not improved despite treatment with tear substitutes. |
Rapid Review complete |
18th January 2016 |
|
| 22021 |
Ciltacabtagene autoleucel |
Carvykti® |
For the treatment of adult patients with relapsed or refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody and have demonstrated disease progression on the last therapy. |
NCPE Assessment Process Complete |
27th September 2023 |
|
| 24021 |
Ciltacabtagene autoleucel |
Carvykti® |
For the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least one prior therapy, including an immunomodulatory agent and a proteasome inhibitor, have demonstrated disease progression on the last therapy, and are refractory to lenalidomide. |
Awaiting full HTA submission from Applicant |
4th September 2024 |
|
| - |
Cladribine |
Mavenclad® |
For the treatment of adult patients with highly active relapsing multiple sclerosis (MS) as defined by clinical or imaging features |
NCPE Assessment process complete |
20th July 2018 |
|
| - |
Clindamycin 1% with tretinoin 0.025% |
Treclinac® |
For the topical treatment of acne vulgaris when comedones, papules and pustules are present in patients 12 years or older. |
Rapid Review complete |
7th May 2014 |
|
| 19045 |
Co-enzyme Q10 |
CoQun® eye drops |
As a complementary add-on treatment to antihypertensive glaucoma therapy. |
Rapid Review complete |
13th January 2020 |
|
| - |
Cobimetinib |
Cotellic® |
For use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. |
NCPE Assessment process complete |
5th January 2017 |
|
| - |
Colesevelam |
Cholestagel® |
Hypercholesterolaemia |
Rapid Review complete |
22nd October 2010 |
|
| - |
Colistimethate sodium |
Colobreathe® |
For the management of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis (CF) aged 6 years and older. |
Rapid Review complete |
28th June 2013 |
|
| - |
Collagenase Clostridium Histolyticum |
Xiapex® |
Treatment of Dupuytren’s contracture in adult patients with a palpable cord. |
Rapid Review complete |
9th June 2011 |
|
| 21017 |
Conestat alfa |
Ruconest® |
For the treatment of acute angioedema attacks in adults, adolescents, and children (aged 2 years and above) with hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency. |
Rapid Review complete |
2nd June 2021 |
|
| 24022 |
Copper Coil |
Yanae® Cu-IUD 380 Mini |
Hormone free intrauterine contraception in women of childbearing age |
Rapid Review complete |
27th June 2024 |
|
| - |
Corifollitropin alfa |
Elonva® |
Controlled Ovarian Stimulation (COS) in combination with a Gonadotropin Releasing Hormone (GnRH) antagonist for the development of multiple follicles in women participating in an Assisted Reproductive Technology (ART) program. |
Rapid Review complete |
22nd October 2010 |
|
| - |
Crizotinib |
Xalkori® |
Treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) (i.e. in the 2nd / 3rd–line treatment setting) |
NCPE Assessment process complete |
27th August 2013 |
|
| - |
Crizotinib |
Xalkori® |
For the first-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). |
Rapid Review complete |
25th April 2017 |
|
| - |
Crizotinib |
Xalkori® |
For the treatment of adults with ROS1-positive advanced non-small cell lung cancer (NSCLC). |
Rapid Review complete |
25th April 2017 |
|
| 24027 |
Crovalimab |
Piasky® |
For the treatment of adult and paediatric patients 12 years of age or older with a weight of 40 kg and above with paroxysmal nocturnal haemoglobinuria (PNH): (i) In patients with haemolysis with clinical symptom(s) indicative of high disease activity; (ii) In patients who are clinically stable after having been treated with a complement 5 inhibitor for at least the past 6 months |
Rapid Review complete |
2nd August 2024 |
|
| - |
Cysteamine bitartrate delayed-release |
Procysbi® |
For the treatment of proven nephropathic cystinosis. |
NCPE Assessment process complete |
15th November 2017 |
|
| 23063 |
Cytisine |
Citidaron® |
Cytisine (Citidaron®) is indicated for smoking cessation and reduction of nicotine cravings in smokers who are willing to stop smoking. |
Rapid Review Complete |
5th June 2024 |
|
| - |
Dabigatran |
Pradaxa® |
For the prevention of stroke and systemic embolism in atrial fibrillation |
NCPE Assessment Process Complete |
3rd June 2011 |
|
| - |
Dabigatran |
Pradaxa® |
For the Primary Prevention of Venous Thromboembolic Events in Adult Patients who have undergone Total Hip Replacement or Total Knee Surgery. |
NCPE Assessment Process Complete |
1st September 2008 |
|
| - |
Dabigatran |
Pradaxa® |
For the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. |
NCPE Assessment Process Complete |
13th June 2014 |
|
| - |
Dabrafeib |
Tafinlar® |
For the treatment of adult patients with unresectable or Metastic Melanoma with a BRAF V600 mutation. |
NCPE Assessment Process Complete |
24th June 2014 |
|
| - |
Dabrafenib |
Tafinlar® plus Mekinist® |
In combination with trametinib, is indicated for the adjuvant treatment of adult patients with stage III melanoma with a BRAF V600 mutation, following complete resection. |
NCPE Assessment Process Complete |
19th August 2020 |
|
| - |
Daclatasvir |
Daklinza® |
In combination with other medicinal products for the treatment of chronic hepatitis C (genotype 1,3 and 4) |
NCPE Assessment Process Complete |
29th May 2015 |
|
| - |
Daclizumab |
Zinbryta® |
Indicated in adult patients for the treatment of relapsing forms of multiple sclerosis. |
Rapid review complete |
23rd November 2016 |
|
| - |
Dacomitinib |
Vizimpro® |
Indicated as monotherapy, for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations. |
Rapid review complete |
13th May 2019 |
|
| - |
Dalbavancin |
Xydalba® |
Indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults. |
Rapid review complete |
28th April 2017 |
|
| 24016 |
Dantrolene sodium hemiheptahydrate |
Agilus® |
In combination with adequate support measures, dantrolene sodium hemiheptahydrate is indicated for the treatment of malignant hyperthermia in adults and children of all ages. |
Rapid Review complete |
27th June 2024 |
|
| - |
Dapagliflozin |
Forxiga® |
Indicated in adults aged 18 years and older with Type 2 Diabetes Mellitus to improve glycaemic control as: Monotherapy: When diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance. Add-on combination therapy: In combination with other glucose lowering drugs including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control. |
Rapid review complete |
31st December 2013 |
|
| 22030 |
Dapagliflozin |
Forxiga® |
Indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. |
Rapid review complete |
14th March 2024 |
|
| 22040 |
Dapagliflozin |
Forxiga® |
For the treatment of chronic kidney disease |
Rapid review complete |
14th July 2022 |
|
| 23065 |
Dapagliflozin |
Forxiga® |
Dapagliflozin (Forxiga®) is indicated in adults for the treatment of symptomatic chronic heart failure with left ventricular ejection fraction >40%. |
Rapid Review Complete |
14th March 2024 |
|
| - |
Daratumumab |
Darzalex® |
For the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy. |
NCPE Assessment Process Complete |
13th March 2017 |
|
| - |
Daratumumab |
Darzalex® in combination with bortezomib and dexamethasone |
For the treatment of adult patients with multiple myeloma who have received at least one prior therapy. |
NCPE Assessment Process Complete |
15th March 2019 |
|
| - |
Daratumumab in combination with lenalidomide and dexamethasone |
Darzalex® |
For the treatment of adult patients with multiple myeloma wo have received at least one prior therapy. |
Rapid review complete |
27th November 2017 |
|
